Warfarin News and Research

RSS

Warfarin is a drug that prevents blood from clotting. It belongs to the family of drugs called anticoagulants (blood thinners).

Risk-adjusted TTR appears to improve anticoagulation control

Researchers from Boston University School of Medicine and the Bedford VA Medical Center believe that risk-adjusted percent time in therapeutic range should be used as part of an effort to improve anticoagulation control and thus improve patient outcomes.

4 Jan 2011

Vicus initiates VT-122 Phase 2 trial in advanced liver cancer, systemic inflammation and cachexia

Vicus Therapeutics, LLC, today announced the initiation of a Phase 2 trial evaluating VT-122, a novel investigational combination of etodolac and propranolol, and Nexavar® (sorafenib) tablets, as a potential new treatment option for patients with advanced liver cancer (hepatocellular carcinoma), systemic inflammation and cachexia.

28 Dec 2010

New era for anticoagulant therapy

In a Guest Editorial published in the new publication Clinical Investigation, Dr Jeffrey Weitz and Dr John Eikelboom of McMaster University in Hamilton, Canada highlight the importance of the approval in October by the FDA of dabigatran etexilate (Pradaxa®; Boehringer Ingelheim). This new oral thrombin inhibitor provides an alternative to warfarin for long-term stroke prevention in patients with non-valvular atrial fibrillation.

22 Dec 2010

Top ten advances in cardiovascular, stroke research in 2010

Research on reducing risks, improving medical treatment and improving lifestyle behaviors to fight the battle against heart disease and stroke are among the key scientific findings that make up this year's top cardiovascular and stroke research recognized by the American Heart Association/American Stroke Association.

22 Dec 2010

23andMe project aims at validating highly scalable pharmacogenomics research

23andMe has launched a project funded by the National Institutes of Health which is aimed at validating 23andMe's highly-scalable platform for pharmacogenomics research. The company received $190,000 in stimulus funding from the American Recovery and Reinvestment Act of 2009 for "Web-based Phenotyping for Genome-Wide Association Studies of Drug Response" from NIH's National Human Genome Research Institute.

17 Dec 2010

Positive results from large, multi-center Canadian trial with On-X Prosthetic Heart Valve

On-X® Life Technologies, Inc., today announced the publication of results of a large, prospective multi-center Canadian trial with the On-X® Prosthetic Heart Valve in the November issue of The Journal of Thoracic and Cardiovascular Surgery.1 According to the results of the report, "The On-X mechanical prosthesis provides favorable intermediate-term results with regard to major thromboembolism, hemorrhage and composites of valve-related complications."

15 Dec 2010

Warfarin may not be beneficial to some patients with atrial fibrillation: Researchers

Researchers at the University of Cincinnati and Massachusetts General Hospital have found that warfarin, a known anticoagulation (blood-thinning) drug, may not be as beneficial to some patients with atrial fibrillation as previously thought.

9 Dec 2010

Sermo releases report on potential replacements for warfarin

Sermo, the world's largest online community for physicians, today announced a free Sermo Report titled, "Potential Replacements for Coumadin (warfarin)." The report gathered feedback from physicians about awareness and understanding of these products and potential barriers to prescribing.

4 Dec 2010

Daiichi Sankyo completes patient enrollment in Phase III edoxaban study for AF

Daiichi Sankyo Company, Limited (TSE: 4568) announced today that it has successfully completed patient enrollment for its Phase III ENGAGE AF-TIMI 48 clinical study of edoxaban, a direct, specific, oral Factor Xa inhibitor that is being investigated in two different dosing regimens given once daily, to prevent the occurrence of strokes and systemic embolic events (SEE) in patients with atrial fibrillation (AF).

2 Dec 2010

VYTORIN reduces major vascular events in patients with chronic kidney disease

In a new investigational study of VYTORIN, the cholesterol-lowering medicine from Merck, VYTORIN 10/20 mg reduced the incidence of first major vascular events defined as non-fatal heart attacks or cardiac death, stroke or any revascularization procedure by a highly statistically significant 16.1 percent compared to placebo, Study of Heart and Renal Protection study involved more than 9,000 patients who, on average, had advanced or end-stage chronic kidney disease (CKD)

22 Nov 2010

Bristol-Myers Squibb, Pfizer discontinue Phase 3 APPRAISE-2 trial in patients with ACS

Bristol-Myers Squibb Company and Pfizer today reported that the companies have discontinued the Phase 3 APPRAISE-2 clinical trial in patients with recent Acute Coronary Syndrome (ACS) treated with apixaban or placebo in addition to mono or dual antiplatelet therapy.

19 Nov 2010

Warfarin taken along with herbal, dietary supplements may be dangerous

Herbal and dietary supplements are popular. People claim they make their joints feel better, their bones stronger, and their hearts healthier. But a recent study by researchers at the Intermountain Medical Center Heart Institute in Salt Lake City shows that many of these people may not realize their favorite supplement, mixed with prescription medications, may be putting their lives in danger, especially if they are taking warfarin - a blood-thinning medication commonly prescribed to patients living with atrial fibrillation to lower their risk of stroke.

17 Nov 2010

Pharmigene receives patent for methods to detect genetic alleles in SJS and TENS

Pharmigene, a leader in advancing personalized medicine and reducing severe adverse reactions to drugs through genetic-based diagnostic solutions, announced it has been granted patents in the United States, Europe, Australia, Singapore and Taiwan. The patents cover methods to detect the presence of key genetic alleles in individual patients being considered for treatment with drugs that have been linked to the development of adverse drug reactions including Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis.

17 Nov 2010

Anti-stroke blood thinner shows promise in large clinical trials

In new and extensive clinical trials an experimental blood thinner called rivaroxaban is at least as good at preventing strokes as the drug warfarin – that has been the most widely used agent for the past five decades in people with erratic heartbeats called atrial fibrillations. Researchers said this Monday that this drug also sharply reduces the risk of major bleeding that is seen with warfarin.

16 Nov 2010

Bayer presents results from Phase III ROCKET AF trial for atrial fibrillation at American Heart Association

Bayer today announced the results from the pivotal, double-blind Phase III, ROCKET AF trial. In the study, rivaroxaban demonstrated superiority to warfarin in reducing the risk of stroke and non-CNS systemic embolism in patients with atrial fibrillation (AF).

16 Nov 2010

Emerging blood thinners to prevent stroke

As blood thinners emerge in the market for stroke prevention many experts believe is still too early to predict how they will stack up in the $15 billion a year market.

15 Nov 2010

Results of RE-LY trial evaluating Pradaxa capsules to be presented at American Heart Association Session

Results of two pre-specified sub-study analyses of the 18,113 patient RE-LY trial, involving the newly approved oral anticoagulant Pradaxa (dabigatran etexilate mesylate) capsules, will be presented at the American Heart Association's Annual Scientific Sessions on Monday, November 15, 2010.

12 Nov 2010

Researchers hope to prevent VTE complication in cancer patients

A major study is under way at The University of Nottingham which could lead to better prevention of a serious and sometimes fatal complication in cancer patients.

12 Nov 2010

Dabigatran etexilate benefits AF patients with previous stroke or transient ischemic attack

Today, The Lancet Neurology published positive results from a sub-group analysis of the landmark Randomized Evaluation of Long-Term Anticoagulant Therapy (RE-LY®) trial - the largest atrial fibrillation (AF) outcomes trial ever completed (18,113 patients in 44 countries worldwide). The new findings fully support the convincing results from the RE-LY® trial and show that AF patients with previous stroke or transient ischemic attack (TIA) may benefit substantially from treatment with dabigatran etexilate.

9 Nov 2010

Atritech commences enrollment in WATCHMAN Left Atrial Appendage Closure Device study in AF patients

Atritech, Inc. today announced initial enrollment into its confirmatory study, PREVAIL, comparing the WATCHMAN® Left Atrial Appendage Closure Device to long term warfarin therapy in patients with atrial fibrillation. Doctors at Central Baptist Hospital in Lexington, Kentucky enrolled the first patient.

3 Nov 2010